DM
Deerfield Management Portfolio holdings
AUM
$6.52B
1-Year Est. Return
13.67%
1 Year Est. Return
+13.67%
AUM
$6.52B
AUM Growth
+$1.02B
(+18%)
Holding
173
Top Buys
| 1 | +$209M | |
| 2 | +$130M | |
| 3 | +$105M | |
| 4 |
Cogent Biosciences
COGT
|
+$92.1M |
| 5 |
Inspire Medical Systems
INSP
|
+$67.4M |
Top Sells
| 1 | +$250M | |
| 2 | +$86.3M | |
| 3 | +$48.1M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$48M |
| 5 |
Baxter International
BAX
|
+$42.8M |
Sector Composition
| 1 | Healthcare | 91.92% |
| 2 | Real Estate | 0.38% |
| 3 | Financials | 0.07% |
| 4 | Consumer Staples | 0.07% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Liquidia Corp
LQDA
$2.72B
| – | – |
-1,616,778
|
|
||
152
Pulmonx
LUNG
$73.4M
| – | – |
-1,890,000
|
|
||
153
Medpace
MEDP
$16.5B
| – | – |
-736
|
|
||
|
MREO
154
Mereo BioPharma
MREO
$285M
| – | – |
-6,710,429
|
|
||
155
Moderna
MRNA
$9.42B
| – | – |
-1,000,000
|
|
||
156
Neuropace
NPCE
$530M
| – | – |
-500,000
|
|
||
157
NovoCure
NVCR
$1.26B
| – | – |
-825,119
|
|
||
158
Oscar Health
OSCR
$4.8B
| – | – |
-11,649,591
|
|
||
159
Vaxcyte
PCVX
$5.84B
| – | – |
-225,000
|
|
||
160
RxSight
RXST
$490M
| – | – |
-888,950
|
|
||
161
Simulations Plus
SLP
$408M
| – | – |
-354,089
|
|
||
162
Universal Health Services
UHS
$14.9B
| – | – |
-1,597
|
|
||
163
PACS Group
PACS
$5.25B
| – | – |
-11,421
|
|